DFCI Logo
DFCI Logo
Michael Hassett, MD, MPH

Michael Hassett, MD, MPH

Medical Oncology
MAKE AN APPOINTMENT

Contact Information

Office Phone Number

617-632-3800

Fax

617-632-1930

Appointments

617-632-2175 (new patients)
617-632-3800 (established patients)

On This Page

Biography

Michael Hassett, MD, MPH

Dr. Hassett received his MD from the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo and his MPH from the Harvard T.H. Chan Scholl of Public Health.  After serving as a Resident and Chief Resident in Internal Medicine at the University of Rochester in Rochester, NY, he went on to complete a fellowship in Medical Oncology at Dana-Farber Cancer Institute & Mass General Brigham.  Since joining the Dana-Farber staff in 2005, he has worked as a medical oncologist in the breast cancer clinic.  In addition, he is the Chief Quality Officer for Dana-Farber and a health systems researcher.  His research focuses on identifying major gaps in the quality of care delivered to cancer patients, and developing and deploying solutions that improve outcomes, reduce disparities, and maximize quality of life.

Researcher

Physician

Chief Quality Officer
Physician
Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

Breast cancer, Breast cancer in men

Diseases Treated

Board Certification

  • Internal Medicine, 2001
  • Medical Oncology, 2005

Fellowship

  • Dana-Farber/Partners CancerCare

Residency

  • University of Rochester Medical Center/Strong Memorial Hospital, Chief Medical Resident
  • University of Rochester Medical Center/Strong Memorial Hospital, Internal Medicine

Medical School

  • State University of New York, Buffalo School of Medicine

Research

    View Dr. Hassett’s Research

    Health services research, Breast oncology

    The main focus of my work involves measuring and improving quality of care, assessing outcomes, evaluating spending, and characterizing the value of cancer care.  Current major research projects include evaluating the quality of care offered to minority and economically disadvantaged women with breast cancer using linked cancer registry-Medicaid claims data, developing algorithms that identify patients with recurrent cancer using claims/electronic health record data, and studying the impact of initial treatment decisions for DCIS on the odds and type of recurrence.  Recently, I have published on the adoption of gene expression profile testing and its association with the use of chemotherapy among women with hormone-receptor positive breast cancer.  The long term goals of my work are to understand how healthcare policies, systems of care, and reimbursement models improve quality, impact outcomes, and increase value.

    Research Departments

    Support my research

    Publications

      View Dr. Hassett's Publications

      • Disparities in electronic health record portal access and use among patients with cancer. J Natl Cancer Inst. 2024 Mar 07; 116(3):476-484. View in: Pubmed

      • Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial. J Natl Cancer Inst. 2024 Mar 05. View in: Pubmed

      • Identifying Oncology Clinical Trial Candidates Using Artificial Intelligence Predictions of Treatment Change: A Pilot Implementation Study. JCO Precis Oncol. 2024 Mar; 8:e2300507. View in: Pubmed

      • Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024 Feb 29. View in: Pubmed

      • Publisher Correction: Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. Nat Med. 2024 Feb; 30(2):607. View in: Pubmed

      • Strategies for Implementing an Electronic Patient-Reported Outcomes-Based Symptom Management Program Across Six Cancer Centers. Res Sq. 2024 Jan 24. View in: Pubmed

      • The Longitudinal Implementation Strategy Tracking System (LISTS): feasibility, usability, and pilot testing of a novel method. Implement Sci Commun. 2023 Nov 28; 4(1):153. View in: Pubmed

      • Assessing Patient Readiness for an Electronic Patient-Reported Outcome-Based Symptom Management Intervention in a Multisite Study. JCO Oncol Pract. 2024 Jan; 20(1):77-84. View in: Pubmed

      • Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials. JNCI Cancer Spectr. 2023 Oct 31; 7(6). View in: Pubmed

      • Feasibility of Weekly Electronic Health Record-Embedded Patient-Reported Outcomes for Patients Starting Oral Cancer-Directed Therapy. JCO Clin Cancer Inform. 2023 09; 7:e2300043. View in: Pubmed

      • Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. Nat Med. 2023 08; 29(8):2057-2067. View in: Pubmed

      • Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool. Eur J Cancer. 2023 08; 189:112930. View in: Pubmed

      • Survival in male breast cancer over the past 3 decades. J Natl Cancer Inst. 2023 04 11; 115(4):421-428. View in: Pubmed

      • Association of Variation in US County-Level Rates of Liver Surgical Resection for Colorectal Liver Metastasis With Poverty Rates in 2010. JAMA Netw Open. 2023 02 01; 6(2):e230797. View in: Pubmed

      • Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study. Breast. 2023 Feb; 67:89-93. View in: Pubmed

      • Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patients. Res Sq. 2023 Jan 10. View in: Pubmed

      • Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer. JCO Precis Oncol. 2023 01; 7:e2200342. View in: Pubmed

      • Variation in Cardiac Dose Explains a "Fraction" of the Disparities Among Breast Cancer Patients. J Natl Cancer Inst. 2022 12 08; 114(12):1570-1571. View in: Pubmed

      • MatchMiner: an open-source platform for cancer precision medicine. NPJ Precis Oncol. 2022 Oct 06; 6(1):69. View in: Pubmed

      • Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. Cancer. 2022 Nov 01; 128(21):3796-3803. View in: Pubmed

      • Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments. Curr Oncol. 2022 08 16; 29(8):5774-5791. View in: Pubmed

      • Framework for integrating electronic patient-reported data in routine cancer care: an Oncology Intake Questionnaire. JAMIA Open. 2022 Oct; 5(3):ooac064. View in: Pubmed

      • Regional Disparities in the Use and Delivery of Adjuvant Radiation Therapy after Lumpectomy for Breast Cancer in the Medicare Population. Adv Radiat Oncol. 2022 Nov-Dec; 7(6):101017. View in: Pubmed

      • Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool. Eur J Cancer. 2022 09; 173:20-29. View in: Pubmed

      • Barriers to Electronic Patient-Reported Outcome Measurement Among Patients with Cancer and Limited English Proficiency. JAMA Netw Open. 2022 07 01; 5(7):e2223898. View in: Pubmed

      • Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial. Trials. 2022 Jun 16; 23(1):506. View in: Pubmed

      • User-centered design and agile development of a novel mobile health application and clinician dashboard to support the collection and reporting of patient-reported outcomes for breast cancer care. BMJ Surg Interv Health Technol. 2022; 4(1):e000119. View in: Pubmed

      • Geospatial Disparities in the Treatment of Curable Breast Cancer Across the US. JAMA Oncol. 2022 Mar 01; 8(3):445-449. View in: Pubmed

      • Global challenges and policy solutions in breast cancer control. Cancer Treat Rev. 2022 Mar; 104:102339. View in: Pubmed

      • Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort. JCO Precis Oncol. 2022 01; 6:e2100232. View in: Pubmed

      • eSyM: An Electronic Health Record-Integrated Patient-Reported Outcomes-Based Cancer Symptom Management Program Used by Six Diverse Health Systems. JCO Clin Cancer Inform. 2022 01; 6:e2100137. View in: Pubmed

      • Correction to: Time-Driven Activity-Based Costing in Breast Cancer Care Delivery. Ann Surg Oncol. 2021 Dec; 28(Suppl 3):899. View in: Pubmed

      • ASO Visual Abstract: Time-Driven Activity-Based Costing (TDABC) in Breast Cancer Care Delivery. Ann Surg Oncol. 2021 Dec; 28(Suppl 3):599-600. View in: Pubmed

      • Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 11; 26(11):927-933. View in: Pubmed

      • Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer. Value Health. 2022 01; 25(1):69-76. View in: Pubmed

      • Regarding the Utility of Unstructured Data and Natural Language Processing for Identification of Breast Cancer Recurrence. JCO Clin Cancer Inform. 2021 09; 5:1024-1025. View in: Pubmed

      • Time-Driven Activity-Based Costing in Breast Cancer Care Delivery. Ann Surg Oncol. 2022 Jan; 29(1):510-521. View in: Pubmed

      • Correction to: Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):305. View in: Pubmed

      • Clinical Inflection Point Detection on the Basis of EHR Data to Identify Clinical Trial-Ready Patients With Cancer. JCO Clin Cancer Inform. 2021 06; 5:622-630. View in: Pubmed

      • Artificial intelligence in oncology: Path to implementation. Cancer Med. 2021 06; 10(12):4138-4149. View in: Pubmed

      • Landscape Analysis of Oncology Mobile Health Applications. JCO Clin Cancer Inform. 2021 05; 5:579-587. View in: Pubmed

      • Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):203-212. View in: Pubmed

      • Population-based estimates of survival among elderly patients with brain metastases. Neuro Oncol. 2021 04 12; 23(4):661-676. View in: Pubmed

      • Leveraging mobile health technology and research methodology to optimize patient education and self-management support for advanced cancer pain. Support Care Cancer. 2021 Oct; 29(10):5741-5751. View in: Pubmed

      • Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. J Natl Compr Canc Netw. 2021 03 10; 19(7):797-804. View in: Pubmed

      • Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021 Jun; 187(3):843-852. View in: Pubmed

      • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021 02 20; 39(6):685-693. View in: Pubmed

      • Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology. Clin Trials. 2020 12; 17(6):597-606. View in: Pubmed

      • Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. Radiat Oncol. 2020 Aug 17; 15(1):198. View in: Pubmed

      • Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes. JCO Clin Cancer Inform. 2020 08; 4:680-690. View in: Pubmed

      • Assessment of Temporal Selection Bias in Genomic Testing in a Cohort of Patients With Cancer. JAMA Netw Open. 2020 06 01; 3(6):e206976. View in: Pubmed

      • Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397. View in: Pubmed

      • Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. Breast Cancer Res Treat. 2020 May; 181(1):43-51. View in: Pubmed

      • Management of Male Breast Cancer: ASCO Guideline Summary. JCO Oncol Pract. 2020 08; 16(8):e839-e843. View in: Pubmed

      • Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol. 2020 06 01; 38(16):1849-1863. View in: Pubmed

      • Commentary: Creating a patient-centered decision aid for ductal carcinoma in situ. Breast J. 2020 07; 26(7):1498-1499. View in: Pubmed

      • Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. Cancer Med. 2020 03; 9(6):2019-2029. View in: Pubmed

      • Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discov. 2020 04; 10(4):526-535. View in: Pubmed

      • Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes. Oncologist. 2020 02; 25(2):91-93. View in: Pubmed

      • Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes. Oncologist. 2019 Nov 19. View in: Pubmed

      • Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. JAMA Oncol. 2019 Oct 01; 5(10):1421-1429. View in: Pubmed

      • Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease. J Oncol Pract. 2019 07; 15(7):e616-e627. View in: Pubmed

      • Performance of Cancer Recurrence Algorithms After Coding Scheme Switch From International Classification of Diseases 9th Revision to International Classification of Diseases 10th Revision. JCO Clin Cancer Inform. 2019 03; 3:1-9. View in: Pubmed

      • Determining the Time of Cancer Recurrence Using Claims or Electronic Medical Record Data. JCO Clin Cancer Inform. 2018 12; 2:1-10. View in: Pubmed

      • What drives variation in spending for breast cancer patients within geographic regions? Health Serv Res. 2019 02; 54(1):97-105. View in: Pubmed

      • Use of Patient-Reported Outcome Measures in Quality Oncology Practice Initiative-Registered Practices: Results of a National Survey. J Oncol Pract. 2018 10; 14(10):e602-e611. View in: Pubmed

      • How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated? Oncologist. 2019 07; 24(7):867-871. View in: Pubmed

      • Increasing Burden of Prior Authorizations in the Delivery of Oncology Care in the United States. J Oncol Pract. 2018 09; 14(9):525-528. View in: Pubmed

      • Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis. Health Serv Res. 2018 12; 53(6):5106-5128. View in: Pubmed

      • Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer. JNCI Cancer Spectr. 2018 Apr; 2(2):pky024. View in: Pubmed

      • Estrogen-receptor status and risk of contralateral breast cancer following DCIS. Breast Cancer Res Treat. 2018 Oct; 171(3):777-781. View in: Pubmed

      • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018 08 10; 36(23):2433-2443. View in: Pubmed

      • Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ. J Natl Compr Canc Netw. 2018 04; 16(4):387-394. View in: Pubmed

      • Chemotherapy medication errors. Lancet Oncol. 2018 04; 19(4):e191-e199. View in: Pubmed

      • Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm. J Natl Cancer Inst. 2018 03 01; 110(3):273-281. View in: Pubmed

      • Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer. JAMA. 2018 01 16; 319(3):306. View in: Pubmed

      • Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Res Treat. 2018 Apr; 168(3):727-737. View in: Pubmed

      • Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. Med Care. 2017 12; 55(12):e88-e98. View in: Pubmed

      • Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat. 2018 02; 167(3):751-759. View in: Pubmed

      • Usability Considerations in Oncology Electronic Medical Records. J Oncol Pract. 2017 08; 13(8):539-541. View in: Pubmed

      • Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death. Health Serv Res. 2018 08; 53(4):2118-2132. View in: Pubmed

      • Quality Improvement in the Era of Big Data. J Clin Oncol. 2017 10 01; 35(28):3178-3180. View in: Pubmed

      • Survival after recurrence of stage I-III breast, colorectal, or lung cancer. Cancer Epidemiol. 2017 08; 49:186-194. View in: Pubmed

      • Implementation of the 21-gene recurrence score test in the United States in 2011. Genet Med. 2016 10; 18(10):982-90. View in: Pubmed

      • Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78. View in: Pubmed

      • Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community. Breast Cancer Res Treat. 2016 Feb; 155(3):541-9. View in: Pubmed

      • Challenges and Opportunities in Delivering High-Quality Cancer Care: A 2016 Update. Am Soc Clin Oncol Educ Book. 2016; 35:e294-300. View in: Pubmed

      • Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment. Cancer. 2016 Feb 01; 122(3):420-31. View in: Pubmed

      • Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. Med Care. 2015 Jul 29. View in: Pubmed

      • Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. Int J Radiat Oncol Biol Phys. 2015 Nov 01; 93(3):622-30. View in: Pubmed

      • Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; 121(12):1937-48. View in: Pubmed

      • Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer. Health Aff (Millwood). 2014 Oct; 33(10):1793-800. View in: Pubmed

      • Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2014 Oct; 52(10):e65-73. View in: Pubmed

      • The relationship between quality, spending and outcomes among women with breast cancer. J Natl Cancer Inst. 2014 Oct; 106(10). View in: Pubmed

      • High-priority topics for cancer quality measure development: results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit. J Oncol Pract. 2014 May; 10(3):e160-6. View in: Pubmed

      • Implementation of chemotherapy treatment plans (CTP) in a large comprehensive cancer center (CCC): The key roles of infrastructure and data sharing. J Clin Oncol. 2013 Nov; 31(31_suppl):20. View in: Pubmed

      • Utilization of cardiac monitoring tests in women with nonmetastatic breast cancer treated with trastuzumab. Per Med. 2013 Sep; 10(7):703-708. View in: Pubmed

      • What does breast cancer treatment cost and what is it worth? Hematol Oncol Clin North Am. 2013 Aug; 27(4):829-41, ix. View in: Pubmed

      • Do drug interaction alerts between a chemotherapy order-entry system and an electronic medical record affect clinician behavior? J Oncol Pharm Pract. 2014 Jun; 20(3):163-71. View in: Pubmed

      • Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Cancer Inst. 2013 Jun 05; 105(11):774-81. View in: Pubmed

      • Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst. 2013 May 01; 105(9):634-42. View in: Pubmed

      • Cost of cancer care: The impact of disclosure on willingness to pay and treatment preferences. J Clin Oncol. 2012 Dec; 30(34_suppl):15. View in: Pubmed

      • Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions. Cancer. 2013 Mar 01; 119(5):1065-72. View in: Pubmed

      • Improving electronic oral chemotherapy prescription: can we build a safer system? J Oncol Pract. 2012 Nov; 8(6):e168-73. View in: Pubmed

      • Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst. 2012 Jul 18; 104(14):1102-5. View in: Pubmed

      • Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer. 2012 Dec 15; 118(24):6022-30. View in: Pubmed

      • Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012 Jun 20; 30(18):2218-26. View in: Pubmed

      • US Cancer Center Implementation of ASCO/Oncology Nursing Society Chemotherapy Administration Safety Standards. J Oncol Pract. 2012 Jan; 8(1):7-12. View in: Pubmed

      • Identifying women at risk of delayed breast cancer diagnosis. Jt Comm J Qual Patient Saf. 2011 Dec; 37(12):568-75. View in: Pubmed

      • Use of annual mammography among older women with ductal carcinoma in situ. J Gen Intern Med. 2012 May; 27(5):500-5. View in: Pubmed

      • Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med. 2011 Oct; 13(10):853-60. View in: Pubmed

      • Relative dose intensity (RDI) assessment in an academic center. J Clin Oncol. 2011 Sep 20; 29(27_suppl):139. View in: Pubmed

      • Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res Treat. 2011 Nov; 130(2):619-26. View in: Pubmed

      • Adjuvant hormone therapy use in early-stage breast cancer patients insured by the New York State Medicaid program. J Clin Oncol. 2011 May 20; 29(15_suppl):6031. View in: Pubmed

      • The relationship between cost, quality, and outcomes among women with breast cancer in SEER-Medicare. J Clin Oncol. 2011 May 20; 29(15_suppl):6001. View in: Pubmed

      • Pathologic characteristics of second breast cancers (SBC) among women previously treated for ductal carcinoma in situ (DCIS) with breast conservation. J Clin Oncol. 2011 May 20; 29(15_suppl):1042. View in: Pubmed

      • Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract. 2011 May; 7(3 Suppl):e1s-7s. View in: Pubmed

      • Genomic testing and therapies for breast cancer in clinical practice. Am J Manag Care. 2011 May 01; 17(5 Spec No):e174-81. View in: Pubmed

      • Chemotherapy-related hospitalization among community cancer center patients. Oncologist. 2011; 16(3):378-87. View in: Pubmed

      • Impact of neoadjuvant chemotherapy on breast reconstruction. Cancer. 2011 Jul 01; 117(13):2833-41. View in: Pubmed

      • Using lifetime risk estimates to recommend magnetic resonance imaging screening for breast cancer survivors. J Clin Oncol. 2010 Sep 20; 28(27):4108-10. View in: Pubmed

      • The full burden of cancer. Oncologist. 2010; 15(8):793-5. View in: Pubmed

      • Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer. 2009 Nov 15; 115(22):5166-74. View in: Pubmed

      • Factors influencing changes in employment among women with newly diagnosed breast cancer. Cancer. 2009 Jun 15; 115(12):2775-82. View in: Pubmed

      • Breast cancer testing strategies and the utilization of targeted therapies: Data from the real world. J Clin Oncol. 2009 May 20; 27(15_suppl):e17518. View in: Pubmed

      • Admissions for chemotherapy-related serious adverse effects (CR-SAEs) and rates of mortality among community cancer center patients. J Clin Oncol. 2009 May 20; 27(15_suppl):6571. View in: Pubmed

      • Identifying high-priority quality measures for breast cancer quality improvement using data from a nationally representative sample. J Clin Oncol. 2009 May 20; 27(15_suppl):6507. View in: Pubmed

      • Disparities in breast cancer adjuvant chemotherapy: moving beyond yes or no. J Clin Oncol. 2009 May 01; 27(13):2120-1. View in: Pubmed

      • Breast biopsy patterns and outcomes in Surveillance, Epidemiology, and End Results-Medicare data. Cancer. 2009 Feb 15; 115(4):716-24. View in: Pubmed

      • Behavioral health services for women who have breast cancer. J Clin Oncol. 2009 Feb 10; 27(5):706-12. View in: Pubmed

      • Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer. J Clin Oncol. 2008 Dec 01; 26(34):5553-60. View in: Pubmed

      • Selecting high priority quality measures for breast cancer quality improvement. Med Care. 2008 Aug; 46(8):762-70. View in: Pubmed

      • Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006 Aug 16; 98(16):1108-17. View in: Pubmed

      • Chemotherapy-related serious adverse events and health care expenditures among commercially insured women with breast cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):6000. View in: Pubmed

      • Psychosis associated with hypopituitarism. Gen Hosp Psychiatry. 1998 Jul; 20(4):248-54. View in: Pubmed

      • Pathophysiology of congenital diaphragmatic hernia. XVI: Elevated pulmonary collagen in the lamb model of congenital diaphragmatic hernia. J Pediatr Surg. 1995 Aug; 30(8):1191-4. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute - Chestnut Hill

      300 Boylston Street Newton, MA 02459
      Get Directions

      Dana-Farber Cancer Institute - Chestnut Hill

      Location Avtar

      Dana-Farber Cancer Institute - Chestnut Hill

      300 Boylston Street Newton, MA 02459
      Get Direction
      42.3192, -71.1798

      Ratings and Comments

      Michael Hassett, MD, MPH

      About Our Ratings

      Physician Star Rating Comment Block

      Discovery and Insights

      Back to Top